20 March, 2015 by The TZ Newswire Staff Comments Off on Stock Market Uptrend Resumes; Wall Of Worry Still In Place
Stock Market Uptrend Resumes; Wall Of Worry Still In Place
Stocks shifted into a higher gear Friday as the Nasdaq scored a new high. The Nasdaq popped 0.7%, while the S&P 500 beat that with a 0.9% gain. The IBD 50 led with a 1.5% surge. Volume rose on both major exchanges compared to Thursday’s pace. Friday was a quadruple witching day, which tends to inflate volume. IBD’s Market Pulse shifted to ‘uptrend resumes.’ Despite that, individual investors would be wise to be selective in their buying.
20 March, 2015 by The TZ Newswire Staff Comments Off on One Last Look At The Real Economy Before It Implodes – Part 3
One Last Look At The Real Economy Before It Implodes – Part 3
Submitted by Brandon Smith from Alt-Market, Click here for Part I and Part II.
20 March, 2015 by The TZ Newswire Staff Comments Off on Biggest risk to the biotech boom
Biggest risk to the biotech boom
What could derail biotech’s rally, with Geoffrey Porges, Bernstein Sr. Vice President.
20 March, 2015 by The TZ Newswire Staff Comments Off on Watch for stock volatility next week
Watch for stock volatility next week
Stocks, stuck in their own zigzag pattern, remain vulnerable to the whims of unusually volatile currency markets.
20 March, 2015 by The TZ Newswire Staff Comments Off on Jazz Pharma Isn’t Just Narcolepsy-Drug Maker
Jazz Pharma Isn’t Just Narcolepsy-Drug Maker
Jazz Pharmaceuticals (JAZZ) has made its mark as the provider of Xyrem, a drug for the sleep disorder narcolepsy. Jazz may be less known for being among the companies fighting cancer. Its Erwinaze is a treatment for acute lymphoblastic leukemia, which affects more than 5,000 Americans and is the leading cause of cancer in children. Erwinaze sales in Q4 reached $53 million, an increase of 21% from the year-earlier period.
20 March, 2015 by The TZ Newswire Staff Comments Off on Revlimid Still Celgene’s Flagship As Other Drugs Grow
Revlimid Still Celgene’s Flagship As Other Drugs Grow
The cancer drug Revlimid is Celgene’s (CELG) bread and butter, accounting for two-thirds of its product sales. But some of its other drugs are showing higher growth rates than its flagship product. Last year, Revlimid sales rose 16% from 2013. By comparison, sales of Abraxane — a treatment for breast, lung and pancreatic cancer — climbed 31% last year.
20 March, 2015 by The TZ Newswire Staff Comments Off on Should This Stock Be Part Of Your Portfolio’s DNA?
Should This Stock Be Part Of Your Portfolio’s DNA?
Most stocks in Sector Leaders have already broken out, but Illumina (ILMN) could be gearing up to make a move. The stock, which appeared on Thursday’s Sector Leaders, began what looked like the start of a new flat base after striking a Jan. 28 high. But with the past few days’ action, a shallow double-bottom is taking shape. Illumina was featured in this column on Tuesday — at the time it was trying to reclaim its 10-week moving average.